Health and Human Services Secretary Robert F. Kennedy Jr. says he's a "big fan" of peptides and has taken them himself. Whether the compounds are safe and proven is a different question entirely.
Copyright 2024 The Associated Press. All rights reserved.
The Trump Administration is actively moving to make wellness peptides marketed for healing wounds, anti-aging and building muscle more accessible.
The Food and Drug Administration announced this week that it will lift restrictions that the Biden administration placed on them that had barred compounding pharmacies from making them. To facilitate this, a two-day advisory committee meeting is set for late July to evaluate seven compounds, including BPC-157, with a second panel to address five additional peptides by February 2027.
The move follows months of political pressure. Health and Human Services Secretary Robert F. Kennedy Jr., who told podcaster Joe Rogan in February that he is a "big fan" of peptides and has taken them himself, argues the Biden administration overstepped and drove users toward a black market. Kennedy called the reclassification effort a “long-overdue action to restore science, accountability and the rule of law.”
For the clinics, telemedicine platforms and med spas already marketing these injections, this is welcome news. For patients considering them, it raises an important question: Does a potential loosening of restrictions mean these compounds are safe and proven?
The short answer is no — and understanding why requires separating the regulatory debate from the state of the science.
Peptides are short chains of amino acids that act as signaling molecules in the body. The concept is scientifically sound. There are dozens of FDA-approved peptide drugs. GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) are peptides, as are insulin, oxytocin and parathyroid hormone analogs. These drugs went through years of clinical trials, demonstrated safety and efficacy in large, randomized studies and earned FDA’s approval for specific indications.
The wellness peptides flooding clinics today are an entirely different category. Compounds like BPC-157, TB-500, CJC-1295 and ipamorelin are not FDA-approved for any human use. They exist in what regulators have called a gray area: an ambiguous legal territory where they are neither explicitly approved for human use nor formally prohibited. In practice, this had allowed compounding pharmacies and wellness clinics to market and dispense these substances without the clinical trial data the FDA requires of approved drugs.
BPC-157 is perhaps the most widely marketed healing peptide, promoted for tissue repair, gut healing and inflammation. A 2025 systematic review identified 36 studies on BPC-157, of which 35 were preclinical animal studies. Only one involved humans: a small, uncontrolled retrospective study of 12 patients with knee pain. No controlled human trials have demonstrated benefit.
CJC-1295 and ipamorelin stimulate the pituitary to release human growth hormone and are commonly combined for anti-aging, muscle building and fat loss. The only published clinical trial of CJC-1295 in healthy adults was small, short-term and reported no serious adverse reactions. Yet, the long-term safety profile is unknown.
The only controlled human trial of ipamorelin is a phase 2 randomized study for postoperative ileus. It found it was well tolerated but showed no significant benefit over placebo. Separately, preclinical data in mice showed ipamorelin paradoxically increased body fat through growth hormone-independent mechanisms, directly contradicting marketing claims. TB-500 is marketed for systemic wound healing and tissue regeneration. Animal studies are intriguing, but there are no rigorous human trials.
Sermorelin occupies a somewhat more legitimate position: it was FDA-approved as a diagnostic and therapeutic agent for growth hormone deficiency in children and was subsequently withdrawn for commercial rather than safety reasons. Physicians can legally prescribe it off-label through compounding pharmacies. Some small studies have shown modest improvements in lean muscle mass in older adults. Long-term benefit in healthy adults pursuing optimization, however, remains unproven.
Wellness peptide marketing emphasizes theoretical benefits and minimizes real risks. Several safety issues deserve attention.
First, many of these peptides work by stimulating cell growth and angiogenesis (i.e. the formation of new blood vessels). Here’s the issue: same mechanism that might accelerate healing in a torn tendon could accelerate the growth of dormant cancer cells. Researchers have flagged this risk for TB-500, CJC-1295 and ipamorelin.
Cancer risk for BPC-157 is debatable. Some researchers have raised concerns about its angiogenic properties while others are less worried. Regardless, no one knows the magnitude of cancer risk for any of these compounds because human studies simply haven't been done.
Second, peptides that stimulate the growth hormone axis carry the potential for hormonal imbalance, fluid retention, joint pain and insulin resistance. These are side effects well-documented with recombinant human growth hormone. Emerging data also highlight potential heart and mental health risks with medications that promote growth hormone secretion, particularly when give in large doses.
Third is the purity problem. Products sold through gray-market channels are not subject to manufacturing standards. An analysis of counterfeit peptide drugs sold online from Europe found purity as low as 5-75% for certain compounds, with contamination by arsenic at concentrations up to 10 times established toxicity limits for injectable drugs, as well as lead. The Department of Justice has already prosecuted one major compounding operation for distributing unapproved peptides including BPC-157, resulting in a forfeiture of nearly $1.8 million.
Finally, there is a documented placebo effect which, amplified by social media and celebrity endorsements, is a potential mediator of perceived peptide efficacy. This makes it difficult to separate genuine pharmacological effects from expectation without controlled trials.
The FDA’s proposed reclassification has drawn criticism from observers who argue that politics are driving the agency’s decisions rather than science.
This has practical implications for patients: the advisory committee meetings are not an approval process. They are an evaluation forum. Even if the FDA follows the committee’s recommendations and allows compounding to resume, that does not constitute a finding of safety or efficacy. It means the compounds will be more legally accessible, not better studied.
Importantly, none of this means all peptide therapies are without value. GLP-1 drugs are themselves peptides backed by extraordinary clinical evidence. Tesamorelin, a growth hormone-releasing hormone analog, is FDA-approved for HIV-associated lipodystrophy and has a defined safety profile.
For patients interested in peptide therapies, it’s best to start with a primary care physician or endocrinologist, not a med spa whose business model depends on peptide subscriptions.
Ask for the human clinical trial data, not animal studies or patient anecdotes. Ask about regulatory status and manufacturing source: only FDA-registered 503B outsourcing facilities offer quality controls that approximate pharmaceutical standards. Many patients are spending $200–$600 per month on these protocols out-of-pocket. That financial commitment makes skepticism even more warranted.
Ultimately, the underlying science that peptides have powerful physiologic effects is legitimate. But having a mechanism of action that seems beneficial does not necessarily mean safety, and regulatory access is not clinical validation. As a 2026 review in Sports Medicine concluded, rigorous human safety data are scarce and there is potential for serious harm from unapproved peptides.
Therefore, patients using wellness peptides are essentially running their own uncontrolled experiment. That is a choice some will make. But it should be made with clear information, not with the assumption that a government policy shift has resolved questions the science has yet to answer.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。